Posted On: 12/16/2015 11:56:41 AM
Post# of 72446
Theory about the U of Bologna Kevetrin trial business:
If I were the CEO of a company, and a well-respected university approached me about doing a trial they wanted to fund, and my only contribution was supplying material, I'd certainly say yes. But then, after many delays, the university comes back and says, "we didn't get the funding, give us 10-12 million and we'll do it" -- I'd say, forget it.
Why would I do that? The obvious answer is that 1) the university lost credibility and 2) the company feels that its money is better spent elsewhere. 2) is the answer that Leo gave at the meeting.
Now let's see -- why would they think their money is better spent elsewhere? Could it be that CTIX has another Kevetrin clinical trial already in progress that has shown such good results that they don't feel the need to fund a second one? That's my guess -- as well as wanting to use that 10-12 million to study other applications for Brilacidin, like the otitis indication we were talking about earlier this morning.
I really think that the company sees NO need to fund another Kevetrin trial because the Dana-Farber one is going so well. Obviously just my opinion, based on the data that we've gotten from CTIX so far.
If I were the CEO of a company, and a well-respected university approached me about doing a trial they wanted to fund, and my only contribution was supplying material, I'd certainly say yes. But then, after many delays, the university comes back and says, "we didn't get the funding, give us 10-12 million and we'll do it" -- I'd say, forget it.
Why would I do that? The obvious answer is that 1) the university lost credibility and 2) the company feels that its money is better spent elsewhere. 2) is the answer that Leo gave at the meeting.
Now let's see -- why would they think their money is better spent elsewhere? Could it be that CTIX has another Kevetrin clinical trial already in progress that has shown such good results that they don't feel the need to fund a second one? That's my guess -- as well as wanting to use that 10-12 million to study other applications for Brilacidin, like the otitis indication we were talking about earlier this morning.
I really think that the company sees NO need to fund another Kevetrin trial because the Dana-Farber one is going so well. Obviously just my opinion, based on the data that we've gotten from CTIX so far.
(0)
(0)
